Readers may recall at the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC) we wrote about the work of Dr Marcel van den Brink (MSKCC) on how the composition of bacteria in the gut can have an impact on graft-versus-host disease (GvHD), and survival post bone marrow transplant. See post: Can you reduce Graft versus Host Disease GvHD by regulating gut bacteria?
At SITC 2015, we heard from Dr Tom Gajewski (University of Chicago) who presented work from his laboratory, recently published in Science, that shows the gut microbiota can also impact the efficacy of checkpoint inhibitors.
Dr Gajweski is one of the foremost cancer immunotherapy researchers in the United States. He previously spoke with BSB about his work on the STING pathway, and how the tumor microenvironment impacts checkpoint inhibitor efficacy. See post: Tom Gajewski takes the STING out of Cancer.
In his extremely busy schedule at SITC, Dr Gajewski found a few minutes to talk about his latest research and future plans.
Subscribers can login to read more or you can purchase access.
New Orleans – one of the presentations of note at Immunology 2015 (the annual meeting of the American Association of Immunologists) was by Thomas J. Gajewski MD, PhD from the University of Chicago. His presentation on “Innate immune sensing of cancer via the STING pathway” was well worth the trip to New Orleans.
Readers may recall the post we wrote in March on “What is STING and why does it matter in cancer immunotherapy?” It followed the news that Novartis were collaborating with Aduro Biotech (NASDAQ: ADRO) on agonists that activate the STING (Stimulator of Interferon Genes) signaling pathway in immune cells.
I had the privilege to talk with Dr Gajewski (pictured below) after his presentation at AAI.
Excerpts from the interview will feature on Episode 2 of the Novel Targets podcast (@TargetsPodcast). (Do sign up for the Novel Targets Newsletter if you want to be among the first to know when this will air). Subscribers can read more from the interview below.
You should read and/or buy access to this post if you don’t know the answers to the following:
- What role does the tumor microenvironment play in response to cancer immunotherapy?
- How could the tumor microenvironment be a biomarker of response to checkpoint inhibitors?
- Why target the STING pathway?
- Reasons Novartis are collaborating with Aduro Biotech?
- How may a STING agonist be brought to the clinic?
To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.